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Introduction : 
La perfusion isolée de membre (isolated limb perfusion, ou ILP) par TNF-alpha et 
melphalan, utilisés en association, est une stratégie de prise en charge chirurgicale 
des sarcomes non opérables des extrémités. Elle a été en partie développée au 
CHUV dans les années 1990, sous l'impulsion du Professeur F. Lejeune, ancien 
Chef du Service d'oncologie médicale (CePO). Les résultats des 31 premiers 
patients ont été publiés en 2000 dans l'European Journal of Surgical Oncology. 
Les données dans la littérature manquant sur les résultats à long terme, nous avons 
revu tous les patients traités au CHUV depuis 1992 pour tenter des de déterminer 
ces résultats à long terme, en se focalisant sur l'efficacité du traitement, symbolisée 
par le taux de sauvetage de membres, autrement condamnés à l'amputation ou à 
une chirurgie mutilante. 
Matériel et méthode : 
Etude rétrospective. 
De 1992 à mars 2006, 51 patients ont été traités par ILP dans notre institution, 
certains à deux reprises (58 ILP au total). Quatre-vingt-huit pour cent présentaient 
un sarcome de haut grade de malignité, et 84% une tumeur localement avancée 
(T2b NO Mo ou plus). 
Résultats: 
Le follow-up moyen est de 38.9 mois (4-159, médiane 22 mois), on note 21% de 
complications immédiates et 23% de complications tardives ou chroniques. 
Une réponse complète (nécrose totale ou disparition de la tumeur) a été observée 
dans 25% des cas, une réponse partielle (>50% de nécrose ou de diminution de 
taille tumorale) dans 42%, une stabilité de la maladie dans 14% et une progression 
tumorale dans 14%. 
Un traitement adjuvant a été entrepris dans 31 % des cas, une résection des résidus 
tumoraux a pu être effectuée chez 65% des patients. 
On note un taux de récidive locale de 35% (après 20,3 mois en moyenne) et un taux 
de récidive à distance de 45% (après 13,4 mois en moyenne). Le disease-free 
survival est de 14,9 mois et la survie à 5 ans de 43,5%. 
Le taux d'amputation s'élève à 24%. 
Conclusion. 
La perfusion isolée de membre est un traitement grevé d'un taux élevé de 
complications, mais il peut être entrepris dans les sarcomes les plus sévères avec un 
succès significatif. Ainsi, dans notre série, une chirurgie mutilante (en général 
l'amputation) a pu être épargnée à 76% des patients. 
Journal of Surgical Oncology 2008;98:148-155 
lsolated limb Perfusion With Tumor Necrosis factor and Melphalan for 
Non-Resectable Soft Tissue Sarcomas: long-Term Results on Efficacy and 
li1nb Salvage in a Selected Croup of Patients 
STÉPHANE CHERIX, MD,1* MÉLANIE SPEISER, MD/ MAURICE MATTER, MD,3 WASSIM RAFFOUL, MD4 
DANIÈLE LIÉNARD, MD,5 NICOLAS THEUMANN, MD,6 ELYAZID MOUHSINE, MD,1 
RENÉ-OLIVIER MIRIMANOFF, MD/ SERGE LEYVRAZ, MD,5 
FERDY J LEJEUNE, MD,5 PIERRE-FRANÇOIS LEYVRAZ, MD1 
1 Department of 01thopaeclic Surgery, University Hospital, Lausanne, Switzerlancl 
. 
2 University Policlinics, Lausanne, Switzerland 
3 Department of Visceral Surgery, University Hospital, Lausanne, Switzerlancl 
4 Department of Plastic and Reconstructi1'e Surgery, University Hospital, Lausanne, Switzerland 
5Multiclisciplinary Oncology Center, University Hospital, Lausanne, Switzerlancl 
6 Depa1tment of Racliology, Uni1,ersity Hospital, Lausanne, Switzerlancl 
7 Depa1tment of Raclio-onco/ogy, University Hospital, Lausanne, Switzerland 
Background and Objectives: Isolated limb perfusion with TNF-alpha and melphalan (TM-ILP) is a limb salvage therapy for non-resectable soft 
tissue sarcomas (STS) of the extremilies. Il is indicated for patients for whom amputation or debilitating surgery is the only alternative. lt can be 
uscd cither as an exclusive thcrapy (in palliation) or as a nco-adjuvant trcatmcnt. followed by marginal resection of turnor remnants with minimal 
functional impairment. 
Methods: Between February ll)')2 and March 2006, 57 TM-ILPs were perfonned on 5 l patients wilh 881)1, high grade and 84% advanced stage 
tumors. 
Results: Mean follow-up is 38.9 months (4-159, rnedian 22 months). Twenty-one percent patients had significant early complications, with 
3 major re-operations, imd 23%> suffered long-lasting complications. Cornplele response was observed in 25%, partial response in 42%, slable 
discase in 14% and progressive discasc in l4%. Rcscetion of the tumor remnants was possible in 65%. A eornplcmentary trcatrnent was ncccssary 
in 31 %, mostly radü1tion thernpy. A local recurrence was observed in 35%, after a mean of 20.3 months (2-78). and distant relapse was seen in 
45%. after a mean of l3.4 months (5-196). Mean Disease-free survival was 14.9 months, and overall 5-year-survival 43.5%. Amputation rate al 
5 ycars was 24%. 
Conclusions: TM-ILP is a conservative treatment with a high complications rate, but it can be successful even for the most severe STS of 
extremities. As a consequence the lirnb can be spared frmn amputation or debilitating surgery on the long terrn in about 75% of patients . 
.!. Sw;q. Oncol. 2008;98:148-155. © 2008 Wiley-Liss, Inc. 
KEY Wmms: advanced extremity sarcomas; local treatment; nmltidisciplinary team work; prevention of amputation 
INTRODUCTION 
Soft tissue sarcomas (STS) account for approximately 1 % of ail 
newly diagnosed lumors; over 50% arise in the extremities [ 1.2]. Limb-
sparing surgery, generally associated with radiation therapy, can be 
successfully pe1formed in up to 90% of these tumors, whereas 
amputation was the rule in nearly 50% hefore the l980s [3-5]. 
Moreovcr, it has been proven that amputation docs not improve ovcrall 
survival, especially for large deep-seated high grade tumors [6-9]. 
Treatment of the latter is challenging, because of the size and location 
that often makes a surgical extirpation difficult or impossible without 
severe functional impairment. Multiple strategies have been cleveloped 
to improve limb salvage, comprising radiation therapy, chemotherapy 
(intra-arterial or systemic ), or both, delivercd pre- or post-opcrativcly 
[10-15]. 
Isolated limb perfusion (ILP) consists in surgically isolating the 
affectcd extremity by cannulating its vesscls and connccting them to a 
hemt-lung machine. A tourniquet is then applied at the root of the limb 
and an extra-corporeal circulation is achieved in mild hyperthermia. 
Drugs can be pcrfused in concentrations up to 30-fold the levcl 
tolerated in systemic infusion [16]. Leakage is monitored with 
© 2008 Wiley-Liss, Inc. 
radiolabeled albumin or erythrocytes injected in the circuit and then 
rneasured in the precordial region with a scintillation probe [ 17]. 
Creech et al. [18] first described ILP in 1958. The first series 
showed promising results in the management of malignant melanomas, 
but poor response rates for advanced STS [19-21]. Dramatically 
Abbrcvialions: TM-ILP, TNF-melphalan isolatcd limb perfusion; TNF. 
tumor nccrosis factor-alpha; STS, soft tissue sarcoma; CR. complete 
rcsponsc; PR, partial rcsponsc; NC, no change; PD. progressive diseuse; 
NA, not assessable; RO, radical resection; R !, marginal resection; R2, intra-
lesional resection; MFH, malignant fibrous histiocytoma; MRI, magnetic 
resonance imaging; FNCLCC, Fédération Française des Centres de Lutte 
Contre le Cancer (French Federation of Cancer Centers). 
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better results were obtained wilh the combination of high dose 
tmnor necrosis factor-alpha (TNF-alpha) with melphalan. a low 
regional toxicity alkylating agent, first rep01ted in 1992 [22]. Severa! 
multicenter and institutional studies confirmed the high el1icacy of 
TNF and melphalan-ILP (TM-ILP). Completc responsc (CR) rates ncar 
100% were obtained for melanomas and objective response rates 
as high as 80-90% were reported for non-resectable STS, with CR 
between 28% and 70%, and limb salvage reaehing 81-90% [23-27]. 
Inte1feron gamma was initially added for its synergy with TNF-alpha. 
but was then abandoned for it did not prove to give significant better 
rcsults than the double association in TM-ILP [23]. 
The mcchanism whcreby TNF-alpha works has been pmtially 
deciphered (reviewed in Ref. [28]): in the early phase (within minutes), 
it improves penetration of anticanccr agents in cancer cells by enhancing 
permcability of nco-cndothclial ce lis and pcricytcs. In the second phase 
(days). it induces destrnction of neo-angiogenic vessels by apoptosis of 
the cndothelial cclls. and intravascular thrombocytes aggregation by 
local procoaguhmt activity. 
Over time, different drugs (cisplatin, doxorubicin, etc.) and 
conditions have bcen expe1ienccd (truc hypcrthennia, hypoxia, varying 
duration of perfusion) to improve the efficiency of ILP. never reaching 
as high response rates with such a low toxicity profile as with TNF-
alpha and melphalan in rnild hyperthermia (<40°) for 90 min [29,30]. 
Our center actively participnted to the development of TM-ILP for 
the treatment of locally advanced melanomas and sarcomas, with 
around 300 TM-ILPs perfom1ed since 1992. The resul!s of the first 
24 patients with STS was prcviously publishcd in 2000 [31]. The goal 
of the present paper is to discuss the results of TM-ILP for STS on the 
long terrn. We report here that even for the most severe STS of the 
cxtremitics, ILP with TNF and rnclphalan is a conscrvativc trcatrncnt 
that can be successfully undertaken and the limb be saved from 
amputation or debilitating surgery in a great proportion of patients. 
MATERIALS AND METHODS 
Betwcen Fcbruary 1992 and March 2006. 51 patients, 27 women 
and 24 men, were treated in our institution for a locally advanced limb 
STS. Mean age was 54.9 years [range 20-84]. Fifty-seven TM-JLP 
wcre pcrfonned, 6 patients being treated twicc. 
AU patients were selected through the multidisciplinary sarcoma 
board of om Universily Hospital (referral center for an approximate 
one million population), whcre about 120 new cases of soft tissue or 
boue tumors are discussed each year. As our center was one of the 
few in Europe offering this treatment in the 1990s, only a minority 
of patients were coming from the usual rcfcffing population of 
our hospital (12 patients= 24% ). The remaining were referred from 
different oncologie or orthopaedic centers in Switzerland (21 
patients =42%) and from other countries: France (12 patients= 24%) 
or Germany (5 patients= 10%). 
The Faculty of Medicine's ethic commillee gave i,ts approval for the 
treatrnent proccdure. 
The data were obtained from our Multiclisciplinary Oncology 
Center. For the patients not followed in our institution, referring 
practitioncrs were contactcd by mail or phone to collcct the data. For 
most of the patients, because of the distance between treatment and 
review, only the must important follow-up data were available, and il 
was gcnerally not possible to asscss daily living activities or functional 
and satisfaction score. 
Histopathologic Diagnosis, Grading, and Staging 
Table I shows histolopathological diagnoses. Undifferenlittted 
sarcomas (former malignant fibrous histiocytomas MFH) and 
liposarcomas represent more than half of cases with 17 (33%) and 
13 (27%), respectively. Ali histopathologic analyses were perfonned 
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TABLE 1. Histological Diai,>J1oses (n = 51) 
Undifferentiated sarcoma (so-called MFH) 
Liposnrcoma 
Leiomyosarcoma 
Epithelioid sarcoma 
Neurofibrosarcoma 
Rhabdomyosarcoma 
Angîosarcmna 
Synovial sarcoma 
Clear cell sarcoma 
Ostcosarcoma of the soft tissues 
Unknown 
Total 
n 
17 
1-+ 
3 
3 
3 
3 
3 
2 
l 
1 
1 
51 
Ol iO 
34 
27 
6 
6 
6 
6 
6 
4 
2 
2 
2 
100 
by the sarcoma spccialist of our Pathology Department, who is a 
member of the French Federation of Cancer Cente1"s Sarcoma Group 
(FNCLCC). In three instances tissue blocs and microscopy slides were 
sent to the French Sarcoma Group for diagnosis review. 
Tables II, IIla and IIIb display lùstopathological grading and staging 
of the tumors. All tumors were classified for histological grading 
according to the FNCLCC classification [32,33]. There were 88% high 
grade tumors (Il or III). Staging was done according to TNM 
classification of soft tissue sarcornas [34.35]. In 65% of cases the initial 
stage was T2b NO MO, that is. a single large (>5 cm) deep-seated 
tu11101: Thcre wcre 84% stage II-IV tumors (high grade or any grade 
with local or distant spread). 
Patients Characteristics and Past Medical History 
Table IV smnrnarizes the initial characteristics of the patients and 
tumors. Forty-six patients (90%) had tumors located on the lowcr 
extremity. Sarcoma presentation included 38 primary tumors (75%) 
13 local recurrences (25'Yc). Forty patients (79%) presented with a 
single tumor and l l had multiple nodules (2 l % ). The mcan time 
between first symptoms and diagnosis was 22.7 months (0-128). 
Eighteen patients (35o/c,) had prior surgery or their tumor: 4 were 
marginal (Rl) and 14 intratumoral (R2) rcscctions. Elcven patients 
had a surgical biopsy, 8 a core needle biopsy (most of them in our 
hospital. who fuvors this diagnosis method) and 2 a culaneous biopsy. 
In 12 cases the diagnosis mcthod was not spccified. A large amonnt of 
patients were referred to our center after initüù non-oncological 
resections for misdiagnosed soft tissue lumors, which explains the low 
rate of specitic oncologie diagnostic biopsy performed. 
Twenty-seven patients (53%) had no past surgical or oncological 
treatment for their sarcorna, while prior treatments had been performed 
in 24 patients. 5 of them being refcned after multiple resections and 
8 after multimodal treatments including surgery, chemotherapy, and 
radiation therapy. 
Indication for TM-ILP 
In 39% of patients TM-ILP was inclicatcd bccause of local spread 
after previous excisions. In 39%, extracompartmental location of the 
tumor (Fig. 1) or its close relationship to the neurovasculm bundle 
TABLE II. Histological Gracling (FNCLCC, Ref. [32)) 
Grade 1 
Grade 2 
Gra,le 3 
Total 
Il 
5 
17 
29 
51 
10 
33 
57 
100 
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TABLE llla. TNM Classification of the 1\m1ors (UICC TNM Classification 
of Malignant Tumors, New York, 2002) 
TNM n % 
TlaNO MO 3 6 
T2aNOMO 4 8 
T2b NOMO 33 64 
Tlb NI MO 1 2 
T2a Nl MO 1 2 
T2b NI MO 1 2 
TlbNx Ml 2 4 
T2b Nx Ml 2 4 
Tx Nx Mt 1 2 
Unknown 3 6 
Total 51 100 
TABLE Illb. Staging of the Tumors (\VHO Classification of Tumors .• Lyon, 
2002) 
11 % 
Stage IA 0 0 
Stage 1B 5 10 
Stage ITA 3 6 
Stage IIB 4 s 
Stage III 28 54 
Stage IV 8 16 
Unknown 3 6 
Total 51 100 
made it non-resectable. In the last 22%, the size of the tumor. without 
regard to ils location was such that no resection was conceivable. Ali 
indications for TM-ILP werc discussed at our Sarcoma Board. In ail 
patients the only alternative would have been amputation or surgery 
with unacceptable Joss of function. Tumor location in the 51 pati.ents 
werc wrist and hand in 2. forearm in 3. elbow in 2. foot and ankle in 6, 
leg in 9, knee or popliteal fossa in 7 and thigh in 19, while 3 were 
unknown. 
Contraindications 
Mctastatic cliscasc docs not ncccssarily prcclude TM-ILP. There is a 
consensus that such patients in good pe1formance status could 
avoid unnecessary mutilation thanks to TM-ILP. Five patients with 
locoregional and thrce with distant spread were submitted to TM-ILP 
in our institution. 
Patients with known severe arterial occlusive disease (stenosis on 
angiogram or Fontaine stage Ilb or more) of the impliecl limb wcre not 
eligible because perfusion couic! be shunted, loosing the desired 
TABLE IV. Characteristics of the Patients al Diagnosis 
Female/male 
Mean age al ILP proccdure (yo = years old) 
Uppcr/lower extrcmity 
Ptimary tumor 
Local recurrence 
Mean tumor size (cm) 
Single tumor 
Multiple nodules 
Lymph nodes 
Distant metastases 
Delay between lst symptorns and diagnosîs 
(rn = rnonthsl 
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Il 
27/24 
54.8 yo 
5/46 
38 
13 
13.2 
40 
11 
3 
3 
22.7 Ill 
%: range 
53/47% 
20-84 yo 
I0-90% 
75% 
25% 
2-38 
79% 
21c;o 
6% 
6% 
0-128 m 
Fig. 1. 1\venty-fivc-year-old male patient with a subcutaneous 
undiffcrcnciatcd sarcoma ncar the knee joint. grade III. stage T2a, 
NO, MO. a,b: clay 0, c,d: clay 45. eJ: 18 rnonths after tumor rcmnant 
excision, with good fonction and no rccurrence. 
antiturnoral cffect on the hypoperfused pait of the limb and increasing 
the sicle effects on the overperfused part of it. 
Patients wilh severe heart failure (NYHA class III and IV) were not 
eligible bccause of the inability to afford the expected transient 
distributive shock (see Leakage Monitoring and Barly Complications 
Section). 
ECOG status > l, severe organ dysfonction, infection (local or 
systemic), immunosuppression (allograft recipients, drug-induced, 
disease-linked) and significant autoimmune diseuse patients were a1so 
not cligible for TM-ILP. 
Leakage Monitoring and Early Complications 
Throughout perfusion, leakage was monitored using radiolabeled 
albumin injected in the extrncorporeal circulation and measured in the 
precordium with a scintillation probe [36]. No patient suffcred life-
threate1ùng leakage. In the early post-operative phase (hours to days ), 
all the patients experienced some transient distributive shock due to 
leakagc of small amounts of TNF in the systemic circulation after 
discontinuation of the extracorporeiù circulation [37]. All patients were 
admitted in the Intensive Care Unit for al least 24 hr. 
Regional toxicity was described by Wiebcrdink et al. in 1982 [38]. 
We used this classification to evaluate toxicity of the treatment on the 
perfusecl extremity and Lhe WHO classification [39] to monitor the side 
effects of the treatment on gencral health. 
Systemic leakage, when irnpmtant, may yield hematological 
complications due to systemic effects of chemotherapeutic dmgs [40]. 
Sorne patients expeiiencecl cytopenia, with rare cases of agranulocytosis. 
In the present series, tlùs kind of complications dicln't generate 
significant consequences and wi11 not be discussed any further. 
Response Assessment 
TM-ILP response was assessed by measuring vanatlon of the 
longest dimneter and necrosis estimate on monthly MRI, according to 
the RECIST critelia [41]. Aftcr tumor rcmnants excision up- and 
down-grading were then considered. depending on the amount of 
tumoral nccrosis dctennined at microscopie examination as described 
by Eggermont et al. [23]. Thus the single most important factor, that 
determined tumor response, was turnor cells necrosis on microscopie 
examination. 
Resection of the Tmnor Remuants and 
Complementary Treatments 
AH patients were reevaluated in our rnultidisciplinary Sarcorna 
Board. Rcsection of the tumor remnants was clone whenevc1· possible, 
depending on clinical response and general status of patients. Monthly 
MRI examinations were repeated until best tumor response was 
obtaincd; rcsection was then pcrformccl. cithcr in our centcr, or by the 
oncologie orthopacdic surgeon of the rcfcning center. 
Complementary treatments (radiation therapy, chemotherapy or 
combined chcmo- and radiotherapy) were discusscd according to 
tumor grade, response to TM-ILP and resection margins mainly. 
Late Complications 
Due to TNF and melphalan pe1fusion, surgery and/or radiation 
therapy, long-lasting locoregional complications are often observed 
after TM-ILP. Actually, all the patients presented with some degree of 
skin redness or pigmentation, some amount of edema and skin atrophy. 
We have focused on severe long-lasting complications, including 
skin necrosis, ncurological complaints and othcr issues that might 
have notable consequences on daily living or have necessitated new 
treatments. As half of the patients were demi by the time ol' the review, 
and as most of them wcrc coming from al! parts of Switzcrland, France 
and Germany, it was not possible to examine them and determinc a 
functional Jimb score. 
Limb Salvage, Local, Loco-Regional and Distant 
Recurrences, Amputations and Survival 
In calculation of amputation rate, primary amputations wcre those 
pcrforrned dircctly after TM-ILP for unsatisfactory rcsponse to 
treatment or local complications. Secondary amputations were those 
perfonnccl later, cithcr after a lornl relapse or after latc progression of 
an unremovcd primary tumor. 
Recurrences were considered as local when they presented in or 
near the rcsection bec! of the prirnary tumor, for cxarnple in the samc 
segment (thigh, Jcg, ann, forcarrn, etc.) or cornpartment of the limb. 
and loco-regiomù when located in the next segment (for example 
skip metastases in the thigh from a primary turnor of the leg) or in the 
known rcgional lymph nodes of the limbs (poplitcal. ilio-inguinal, 
elbow, or axillary nocles). Local recurrences were always located 
within the perfused area. whereas loco-regional recurrences might 
appear within or outside the perfused area. 
Metastases were considered as distant in ail other situations 
(controlateral Jimb, other extremity or girdle, cerebral or thoraco-
abdominal locations). 
Statistical Methods 
Confidence intervals for ail data were based on the binomial law 
[42]. Amputation Rate, Disease-Free Survival (DFS) and Overall 
Survival curves were established according to the Kaplan-Meier 
(K-M) methods [43]. Survival and local or distant recurrences, as we11' 
as disease-free interval were measured from the date of the TM-ILP. 
Patients still alive were considered as censored observations at the 
date of the last follow-up. Ail data were reviewed by our clinical 
cpidemiologist, who detcnnincd the K-M curves and the rccurrencc 
and survival rates by using the software "R" [44]. 
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TABLE V, Response Rates (51 Patients, 57 ILP) 
Grade 1 Grade 2 Grade 3 Total (n) Total (%) 
Complete response =CR 0 9 5 14 25 
Partial response =PR 2 6 16 24 41 
No change=NC 2 3 3 8 14 
Progressive diseuse= PD 0 2 6 8 14 
Unmeasurable 0 0 0 0 0 
Not evaluable: ILP <3 months 1 l 3 6 
Total 5 21 31 n=57 LOO 
RESULTS 
This retrospective study has a rnean follow-up of 38.9 months 
[range 4-159, mcclian 22 months]. TM-ILP wcre pe1formed betwccn 
Febnuu·y 1992 and march 2006. The data were collected and reviewed 
until June 2006. No patient was lost to follow-up. 
Tmnor Response and Grade-Related Response 
Table V displays the response rates and responses according to the 
histological grade. In 67% of ail 57 TM-ILPs, a major turnor rcsponse 
was observed with 14 (25%) complete response (CR, disappearance of 
ail measurnble disease for >4 weeks on MRI or necrosis 98-100% on 
histopathology analysis) and 24 (42%) partial rcsponsc (PR. rcgrcssion 
of >50% on MRI or necrosis >50%). Eight patients (14%) showed no 
evolution of the diseuse (no change NC), 8 patients ( l 4'Jo) progression 
of the tumor (progressive diseasc PD) and 3 wcrc not full y asscssccl duc 
to a too short follow-up (not assessable NA). 
The six patients undergoing a second TM-ILP showed 1 CR, 2 PR, 
1 NC, 1 PD, and 1 NA (short follow-up). Ail but one (who showcd 
twice a CR) had a worse response following the second TM-ILP. 
A response rnte (CR+ PR) was observed in 40%, grade 1, 74%• grade 
II and 68% grade III sarcomas. No CR was obscrvcd in gracie I turnors, 
which elicited only PR or NC. Six PD out of 8 were observed in grade 
li! tumors. 
Toxicity and Complications 
The mean Intensive Care Unit stay was 2 days (0-11), with 
4 patients staying more than 3 days. 
Twclve patients (21 %) prcscntcd with scrious carly complications. 
of which four hacl a transient nerve palsy (Wieberdink grade 3) 
and one had a compartment syndrome of the thigh (grade 5) who 
evcntually was arnputatcd duc to ongoing scvere sciatic nervc palsy 
combined with extensive skin necrosis. Other severe complications 
included 3 patients with hematologic disorders (WHO grade 2 or 
more), 2 reopcrations in emcrgcncy for rctroperitoneal bleecling, 
one extensive tumor necrosis with early debulking after 13 days, 
2 temporary renal failures, one temporary liver failure and 1 thrombo-
cmbolic discasc, somc of thcm in the samc patient. Ail patients 
sustained at least a Wieberdink grade 2 local reaction (limb edema, 
skin redness). 
Thirteen patients (23%) suffcrcd from late complications: 8 cuta-
neous, 7 long-lasting neurologie (comprising pain and algodystrophy), 
1 articular (elbow stiffness), l orthopedic (femoral nail fatigue 
fracture) and one septic shock. Among 8 patients with cutaneous 
complications, 4 needed multiple plastic surgery procedures to cover 
defects, and 4 had a chronic skin ulcer. Two of them had received 
complementary radiation therapy. 
Two patients sustained both carly and late complications. 
uncorrelated one with the other. 
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Tumor Remnants Excision and 
Complementary Treatment 
Following the first TM-ILP tumor remnants were resected in 
33 patients (65%), while 7 (14%) had to be amputated. Ten distant en 
bloc rcsections (RO), 20 marginal (RI) and 3 intra-tumoral (R2) wcre 
performed. On six patients, because of early appearance of distant 
metastases, no operation was perfom1ed. 
After the second TM-ILP, 1 RI, 1 R2 rcsection and 2 amputations 
were pe1fonned: while 2 patients were treated conservatively. 
Sixteen (31 % ) patients received a complementary treatment: 
radiation therapy in 9, systemic chemotherapy in 3 and combined 
radio- and chemotherapy in 2. 
Recurrence 
Thirty-two patients (63%) suffered from recurrence. Tcn patients 
had distant recurrence alone, 6 local recurrence alone and 4 loco-
regional recurrence alone. Eleven patients sustained both local and 
distant relapse (5 synchronously, 3 locally first, and 3 distantly first), 
and one patient had synchronous local, loco-regional and distant 
relapse. 
Recurrence within pe1fusion area occurred in 19 patients (37%) and 
outside perfusion area in 25 patients (49%). Figure 2 summarizes 
location and disttibution of recuffenccs. 
Local recurrence was diagnosed in 18 patients (35% ). Mean local 
r~crnTence lime from TM-ILP was 20.3 months [range 2-78]. Only 
lngh grade tumors recrnTed locally, from which had elicitcd a 5 CR, 
10 a PR, 2 a NC, and 2 a PD after the first TM-ILP. A RO resection had 
been performed in 5patients,aR1 in 7, a R2 in 2, an mnputation in one 
and no reseclion in 4. Six patients (30% of the patients with a local 
recurrence) were eligible for a second TM-ILP. 
Loco-regional rec11rre11ce was diagnosed in 5 patients ( 1 O'Yc). Mean 
loco-rcgional rccmTcncc timc from TM-ILP was 8.8 months [range 4-
19]. Ali loco-regional recurrences but one were located in regional 
lymph nodes outside the perfusion's areu. They were observed only in 
patients with high grade tumors. 
Distant recurrence cleveloped in 22 patients (43%). Mean time from 
TM-ILP to distant metastases was 13.4 months [range 2-43]. Again 
only patients with high grade tu mors prcscntcd with distant metastascs. 
Loco-regional recurrence 
total= 5 
No recurrence 
16 
Unknown 
3 
n = 51 
Fig. 2. Location and distribution of recurrences. 
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Seventy-seven percent of them were located in the lungs. Initial 
response to TM-ILP had been a CR in 6 (23% ), a PR in 11 (42% ), a NC 
in 4 (15%) and a PD in 5 (19%). · 
Disease-Free and Overall Survival 
Mean DFS from TM-ILP was 14.9 months (2-49). Threc patients 
with distant metastases prior to TM-ILP were not considered. 
Overall survival rates al 2, 5, and 10 years were 60%, 44% and 28% 
respectively. 
Twenty-four patients out of 51 have died (47%) with a mean overall 
survival of23.3 months (4-93). All patients but one died or the disease 
(96%). 
Amputations and Limb Salvage 
Following TM-ILP limb salvage was not possible in 12 patients 
(24%), with 7 primary and 5 secondary amputations, as shown in 
Figure 3. whcre thcre is an carly steep curve co11'Csponding to the 
primary amputations after ILP and it is followed by a linear and 
not steep curve corresponding to the secondary amputations. This 
illustrates that the sccondary amputations wcre duc to the natural 
outcome of the disease not in relation with ILP. 
No specific risk factors could iclentify patients who finally needed 
amputation (emly or Jale) in this heterogeneous group of patients. 
Primary amputation was clecided in 7 patients: 5 had insufficient 
trealment response (NC or PD), one patient lrncl u local multi-operated 
stalus und one patient had a compartment syndrome with complete 
sciatic nerve palsy. Five different histological diagnoses and ail grades 
were present. 
Seco!ldary amputation was performed in 5 patients ( 12%,): two had 
an unsuceessful rcsponsc to a second TM-ILP, two patients had a 
diffuse local relapse and one patient, who refused excision of the 
prirnary tumor after TM-ILP, had a slow progressive disease during 
3.5 ycars.Overall prirnary limb salvage rate was 86%, and the total 
limb sparing 76%. 
DISCUSSION 
This retrospective study is based on u selecled group of patients 
with a very poor prognosis (88% of the patients in this scries had a high 
grade and 84% an advanced staged tumor). It clemonstrates that TM-
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Fig. 3. K-M curves showing the biphasic pattern of amputations 
after TM-ILP (early versus lute events) x-axis = years; y-axis= 
amputation-free proportion. 
ILP is able to offer a limb sparing strategy even for the patients with the 
most aggressive non-rescctable soft tissue sarcoma, observed with a 
long-tenu follow-up more than 10 years. 
While comparing other publications in the literature, the 
present se1ies has the longcst mean follow-up (38.9 months, 4-159) 
with Lev-Chelouehe's study in 1999 who was referring on six desmoid 
tumors [45]. 
It would be cliffieult to have a much longer follow-up while clealing 
with advaneecl high grade sareoma patients, because most of them 
recur ami die within a few years after trentment as presen ted in our 
experience with 40% death rate after 2 years. In our results 44% of 
patients snrvived more than 5 years. This is of notable importance, 
because late relapses and amputations can be observed. 
In fact the amputation rate is one of the highest cvcr published in 
spite of the fact that 3/12 werc submittecl to a second TM-ILP. Late 
amputations up to 3.5 yeru-s after TM-ILP have been identified. One 
may speculatc that the rcal limb salvage in some cohorts is ovenatcd 
because of a shorter follow-up. Likewise local relapse rate (35%) is. 
high compared with other series, but again 5 recurrences were 
obscrved more than 3 years after TM-ILP. The long-tcrm recunence 
rate does not seem to be influenced by longer follow-up, as only 
2 patients recurred more than 3 years after treatment. Lmge differences 
in limb salvage and local relapse can be explained by higher proportion 
of aggressive tumors and longer follow-up, with consequently dif-
ficulties to compare our results with others [23,24,26,29,46,471. 
The 25'Yo complete response (CR) rate or this series is comparable to 
the 28% and 29% CR of the European multiccntcr study published by 
Eggermont et al. in 1996 and 1999 [23,48]. the 29% CR of the 
Rotterdam experience with older patients or van Etten in 2003 [49] and 
the 24% CR in rccurrcnt sarcomas in irracliatcd fields of Grünhagcn in 
2005 [50]. 
CR results repm1ed by Bonvalot et al. in 2005 [51] were also higher 
than otirs. but they wcrc bascd on a ranclomizcd phase Ilb study 
(studying TNF doses) with a consistent proportion of stage lb and lia 
patients. Furthermore CR was considered when 90% necrosis was 
prcscnt on histological examination. whcrcas 98-100% nccrosis wcre 
required in our series f 48-511. With 42% PR. the objective response 
rate is 67%, which is also comparable to the aforementioned studies 
(57-76%). 
Classical early complications related to TM-ILP (local, hemody-
namic, hematological, renal, hepatic, etc.) were present in 21 %·of the 
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patients. ln most of the cases they were transient, predictable and 
successfully managcd. They gcnerated a mean Intensive Care Unit stay 
of 2 days (0-11), with 4 patients staying more than 3 days. They were 
mainly due lo systernic TNF leakage during perfusion distinct from the 
so called "tourniquet effcct," as dcscribed by Christoforidis et al. in 
2003 [37]. These data are not consistently different from what 
bas already been descrihed in the lilerature [28,38,39]. With lwo early 
re-opcrations (3.5%) for bleeding on the cannulation site, this se1ies 
reaches an acceptable complication rate. Scarce data in the recent 
literature makes a global comparison dirticult to establish. No 
treatment-rclatecl clcath was rcportcd. 
With 23% late and long-lasting complications, this serics is also 
comparable to others; local consequences ofTM-lLP can be serions, as 
one patient needcd to be amputatcd one year after treatment becausc of 
a Wieberdink grade 5 complication (thigh compartmcnt syndrome and 
subsequent complete sciatic nerve palsy). Eight patients suffered from 
pennanent skin ulccr or needecl iterative surgcry to cover a cutaneous 
defcct. It is however difficult to distinguish bctwcen tumor-rclatcd 
from TM-ILP-related skin complications. It is worth mentioning that 
only two of the 13 patients with long-lasting complications had 
rcceived complcmcntary radiation therapy. Together with Olicrnan 
et al. [47] and Vrouenraets et al. [52] we think that complementary 
radiotherapy is not contraindicntecl after TM-ILP and excision of tumor 
remuants, as far as local healing is acquired. In order to improve post-
operative ederna, we have introduced early systematic lymphatic 
drainage (in the !CU), mobilization therapy and mild-pressure 
stockings. with subjective promising results, although no objective 
measurements have been performed. 
Tumor remnants excision was performed in 33 patients (65%) after 
the first TM-ILP and in two out of 6 aftcr the second one. Marginal 
resection (Rl) is the rule (20/34). TM-ILP often facilitates surgical 
resection not only because of tumor shrinkage, but also hecause the 
sarcoma is better delincated. The prcvious fragile thin pseuclocapsule is 
replaced by a thick fibrous pseudocapsule. It is constituted by the 
turnor response itself and by surrounding non-tumoral fibrosing tissue 
(Fig. 4 ). The surgeon fine! this resistant pseuclocapsule, which en ables a 
safer null'ginal resection of the tumor remuant with a lower risk for 
positive surgical rnargins or capsule break with tumor spilling in the 
rcscction bed. 
With 76% total limb salvage, our data are within the range of the 
recent literature (from 58% for Noorda et al. in 2003 [27] to 89% for 
Fig. 4. Macroscopic (left) and microscopie (right) pictures of an operative specimen showing extensive necrosis and a thick pseudocapsule 
surrounding the tumor. 
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Santinami el al. in 1996 [24]). Initial TM-ILP and tumor remmml 
excision cven reach 86% plimary limb salvage, which is close to the 
best results published by Santinami et al. in 1996 [24] with 90% limb 
sparing for afler 15 months follow-up. As the primary lreatment 
end-point is amputation or debilitating surgery prcvention, wc may 
consider the present results as satisfactory. 
Local recurrence w~1s observed in 19 patients (37%), which 
compares with others [25,46]. This high rate can be cxplained on 
one hand by a longer mean follow-up (> 3 years) allowing la te 
recmrences registration and on the other hand by a higher proportion of 
high grade and high stage tumorn. Finally wc also get a great arnount of 
recuffences or disseminations in already rnulti-operated patients, who 
were referred to our center for TM-ILP. 
In rnost of the cases local and distant recurrences occnffecl 
sirnultaneously. Systemic rnetastases presented first or synchronously 
in 68%. Ali together, a total of 26 loco-regional or distant recurrences 
(51 % ) wcre obscrvccl. This inclicates that a distant spreacl was probably 
already present by the time of TM-ILP. Actually, al! patients 
with recurrence had a high-grade sarcoma. It confirms that the less 
cliffercntiated the turnor, the more aggressive the biological behavior 
and the higher the risk for relapse, whatever the stage as alreacly 
mentioned. It confirms that local contrai does not correlate with overall 
survival [6-9]. 
Five years survival rate after TM-ILP was 44%, with 96% disease-
related deaths. In 2003, Noorda et al. [27] reported 48% 5-year disease 
specific survival rate, but with 20% grade I and 41 ')!, stage l m1d Il 
lmnors. Other serics do not mention 5-year survival rate becausc of a 
shorter follow-up. 
For soft tissue lirnb sarcomas lreated by classical surgery. Pisters 
mentioncd 76% survival after 5 ycars [53]. This corresponds to the fact 
that a group of patients combining less aggressive sarcomas with ail 
stages together have a better prognosis and cannot be compared with 
our series of patients, that incluclcs 88% high gracie (FNCLCC II and 
III) and 85% >stage IB STS. Patients who couic! afforcl an oncological 
sale resection were sparecl TM-ILP in our Sarcoma Board. Om series 
demonstrates that preservativc trcatment shoulcl be considcrcd in 
orcler to prevent the remaining patients with a poor prognosis from 
mutilation. 
Limitations of this retrospcctivc stucly inclucle difficultics for 
collecting data. Seventy-six percent of patients were coming from 
outside the referring population of our University Hospital and 
more than half had died by the timc the data were collccted. Following 
the publishcd review of the first 24 patients (1992-1998) [31], no 
database or prospective follow-up were available by the lime the 
prcsent review was restarted. Another limitation was the impossibility 
to evaluate any functional outcome or impact on claily living, which 
should ideally be part in a study evalualing a local treatment strategy, 
but this aspect of TM-ILP was thoroughly describecl by Vrouenraets 
et al. in 1999 [46]: he demonstrated 25% global limb atrophy and 40% 
restricted ankle extension after 48 months. 
The present stucly is a rctrospective rcview of aÙ the STS trcatecl by 
TM-ILP in our center. lt is very heterogeneous when reg<mling 
10 clifferent histopathological diagnoses, 11 different TNM and 
6 differcnt stages togethcr in the samc serics. Howcvcr it is homo-
geneous and different from other series in that there are almost only 
high grades (Il and III) and high stages (lia-IV). We might have been 
more selective and exclucle the lower gracies and stages in order to 
cletermine the outcome of the treatment only for high grade and high 
stage tumors, considering that indications to TM-ILP do not depend on 
the histopathologic characteristics of the tumors. However considering 
that al! patients presented criteria of irresectability, we decided not to 
exclucle any patient frorn the review. It is important in thal TM-ILP 
offers long-tenn perspectives of limb salvage in all patients with an 
advanced STS of an extrernity, whatcver the prognosis. It is not 
dedicated only to condemned patients for whom an amputation would 
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significantly worsen the quality oflife during the last months or years 
of thcir existence. 
CONCLUSION 
TM-ILP is a procedure with a high immecliate and late complica-
tions rate. Long-lerm resulls show that, even for the mosl severe soft 
tissue sarcomas of the extremities (88% high grade and 84% advanced 
stage tumors in the present series), this conservative treatment can be 
successfully undertaken and the limb be saved on the long tenn from 
amputation or debilitating surgery in thrce quarters of the patients. 
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